Panel Reactive Antibody Responses Against Influenza Vaccination in Kidney Transplant Recipients |
| |
| Affiliation: | 1. Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University Istanbul, Turkey;2. Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey;3. Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey;1. Department of Surgery, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;2. 2nd Department of Medicine and Cardiology Centre, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;3. 1st Department of Medicine, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;4. Department for Medical Translation and Communication, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;1. Department of Pediatric Nephrology, Ege University Faculty of Medicine, İzmir, Turkey;2. Department of Nephrology, Ege University Faculty of Medicine, İzmir, Turkey;3. Department of Pathology, Ege University Faculty of Medicine, İzmir, Turkey;4. Department of General Surgery, Ege University Faculty of Medicine, İzmir, Turkey;1. Department of General Surgery, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey;2. Department of Pathology, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey;3. Department of Preventive Oncology, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey;1. Department of Nutrition and Dietetics, School of Health, Tekirdağ Namık Kemal University, Tekirdağ, Turkey;2. Department of Nephrology and Transplantation, School of Medicine, University of Health Sciences, İstanbul, Turkey;3. Department of General Surgery, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdağ, Turkey;1. Department of Thoracic Surgery, The National Institute of Oncology, Budapest, Hungary;2. Department of Thoracic Surgery, Semmelweis University, Budapest, Hungary;3. The Heart and Vascular Center of Semmelweis University, Budapest, Hungary;4. Department of Anesthesiology and Intensive Care, The National Institute of Oncology, Budapest, Hungary;5. Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria;1. Division of Organ Transplantation, Institute of Surgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary;2. Department of Surgery, Faculty of Medicine, University of Szeged, Szeged, Hungary;3. Department of Surgery, University of Pecs Medical School, Pecs, Hungary;4. Heart and Vascular Center, Semmelweis University, Budapest, Hungary;5. Pediatric Heart Centre, Gottsegen György National Institute of Cardiology, Budapest, Hungary;6. Department of Thoracic Surgery, National Institute of Oncology-Semmelweis University, Budapest, Hungary;7. National Blood Service, Budapest, Hungary;8. Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary |
| |
| Abstract: | ![]()
IntroductionSeasonal influenza is an important cause of morbidity and mortality in the post-transplant period; therefore, the influenza vaccination has been recommended for all kidney transplant recipients before the influenza season. However, at least theoretically, the introduction of antigens via vaccines may trigger rejection attacks by causing an antibody response. In this study, we examined the development of de novo panel reactive antibody (PRA) development against the influenza vaccine in kidney transplant recipients.Materials and MethodsOverall, 41 kidney transplant recipients who received the influenza vaccination and 50 kidney transplant recipients (study group) who refused to receive the influenza vaccination (control group) were enrolled in the study. Following basal biochemistry examination, the inactivated trivalent influenza vaccine was administered intramuscularly. Panel reactive antibodies were screened in all patients before and after vaccination on days 30 and 180. The primary outcome variable was development of de novo panel reactive antibodies.ResultsOne patient in the study group developed de novo class I and II PRA at 6 months after vaccination (P > .05), while no antibody development was noted in the control group. Graft dysfunction or biopsy-confirmed rejection was not observed during the follow-up period in both groups.ConclusionThe influenza vaccination is generally effective and safe in solid organ transplant recipients. The vaccination procedure has the potential to trigger antibody development and occurrence of rejection. Therefore, vaccinated kidney transplant recipients should be monitored more carefully with regard to PRA; if the graft deteriorates, a rapid transplant biopsy should be performed. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
